Invion
ASX:INVMelbourne, Australia· Est.
Australianion leverages its Photosoft™ PDT platform to develop targeted, low‑toxicity cancer and disease therapies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australianion leverages its Photosoft™ PDT platform to develop targeted, low‑toxicity cancer and disease therapies.
OncologyInfectious DiseasesDental/PeriodontalOphthalmology
Technology Platform
Photosoft™ is a proprietary photodynamic therapy platform that combines next‑generation photosensitizers with optimized light activation to selectively destroy cancer cells or pathogens while minimizing collateral damage.
Opportunities
Successful early‑phase data could unlock fast‑track regulatory pathways and attract partnerships with major pharma seeking novel PDT assets; expansion into veterinary and ophthalmic markets broadens revenue potential.
Risk Factors
Technical challenges in light delivery, uncertain clinical efficacy, and competition from established PDT players could delay commercialization and affect financing.
Competitive Landscape
Invion competes with companies such as Photocure, Medtronic (Halo®), and US‑based PDT innovators, but differentiates through its proprietary Photosoft™ chemistry, broad IP coverage, and multi‑indication licensing strategy.